Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for DVT patients when blood thinners fail

NCT ID NCT06486181

Disease control Sponsor: Rush University Medical Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether using a catheter to deliver clot-busting drugs or a device to physically remove the clot can help people with acute deep vein thrombosis (DVT) who do not improve after one week of blood thinners. About 100 adults aged 18 to 75 with acute DVT in the leg will be randomly assigned to receive either the endovascular procedure plus standard care or standard care alone. Researchers will compare symptom scores and clot burden to see if the extra treatment is safe and effective.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
catheter-directed thrombolysis or mechanical thrombectomy
What this could lead to
If it works, this could provide a safe and effective second-line option for people with acute DVT who do not respond to initial blood thinner therapy.
What could go wrong
This is a relatively small Phase 4 trial (100 participants) and has not yet started recruiting. The procedures carry risks like bleeding or vessel damage, and results may not apply to all DVT patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Apr 2026

An estimate. Start dates often move.

Expected to finish

Apr 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients over 18 years of age * Patients who have diagnosis of acute femoropopliteal acute deep venous thrombus * Patients eligible for anticoagulation treatment Exclusion Criteria: * Patients under 18 years of age * Patients over 75 years of age * Symptoms starting date of more than 14 days * Patients who have contraindication for anticoagulation treatment * Patients who have high bleeding risk (more than 2 of the following risk factors): * Age \>65 years * Previous bleeding * Cancer * Metastatic cancer * Renal failure * Liver failure * Thrombocytopenia * Previous stroke * Diabetes * Anemia * Antiplatelet therapy * Poor anticoagulant control * Comorbidity and reduced functional capacity * Recent surgery in 30 days * Frequent falls * Hemodynamically unstable patients * Patients having severe swelling and pain, cyanosis, and absent pulses consistent with compartment syndrome.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute femoropopliteal deep venous thrombosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

femoral vein thrombophlebitis venous thromboembolism Venous Thrombosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Deep venous thrombosis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • RUSH University Medical Center

    Chicago, Illinois, 60612, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.